Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus
- 1 July 2014
- journal article
- review article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 24 (14) , 2991-3000
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1PLOS ONE, 2013
- DC260126: A Small-Molecule Antagonist of GPR40 that Protects against Pancreatic β-Cells Dysfunction in db/db MicePLOS ONE, 2013
- Discovery of TUG-770: A Highly Potent Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonist for Treatment of Type 2 DiabetesACS Medicinal Chemistry Letters, 2013
- Randomized, Double-Blind, Dose-Ranging Study of TAK-875, a Novel GPR40 Agonist, in Japanese Patients With Inadequately Controlled Type 2 DiabetesDiabetes Care, 2013
- Identification and Pharmacological Characterization of Multiple Allosteric Binding Sites on the Free Fatty Acid 1 ReceptorMolecular Pharmacology, 2012
- A Potent Class of GPR40 Full Agonists Engages the EnteroInsular Axis to Promote Glucose Control in RodentsPLOS ONE, 2012
- TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trialThe Lancet, 2012
- AMG 837: A Novel GPR40/FFA1 Agonist that Enhances Insulin Secretion and Lowers Glucose Levels in RodentsPLOS ONE, 2011
- The Fatty Acid Receptor GPR40 Plays a Role in Insulin Secretion In Vivo After High-Fat FeedingDiabetes, 2008
- Gpr40 Is Expressed in Enteroendocrine Cells and Mediates Free Fatty Acid Stimulation of Incretin SecretionDiabetes, 2008